Objective To compare the effects of 20 mg qd and 10 mg bidadministration of iprrazole enteric-coated tablets on the control of gastric acid in healthy subjects.Methods A randomized,single-center,parallel controlled trial was designed to include 8 healthy subjects.Randomly divided into 2 groups,20 mg qd administration group:20 mg enteric-coated tablets of iprrazole in the morning;10 mg bid administration group:10 mg enteric-coated tablets of iprrazole in the morning and 10 mg in the evening.The pH values in the stomach of the subjects before and 24 h after administration were monitored by pH meter.The plasma concentration of iprazole after administration was determined by HPLC-MS/MS.The main pharmacokinetic parameters were calculated by Phoenix WinNonlin(V8.0)software.Results The PK parameters of iprrazole enteric-coated tablets and reference preparations in fasting group were as follows:The Cmax of 20 mg qd group and 10 mg bid group were(595.75±131.15)and(283.50±96.98)ng·mL-1;AUC0-t were(5 531.94±784.35)and(4 686.67±898.23)h·ng·mL-1;AUC0-∞ were(6 003.19±538.59)and(7 361.48±1 816.77)h·ng·mL-1,respectively.The mean time percentage of gastric pH＞3 after 20 mg qd and 10 mg bid were 82.64％and 61.92％,and the median gastric pH within 24 h were 6.25±1.49 and 3.53±2.05,respectively.The mean gastric pH values within 24 h were 5.71±1.36 and 4.23±1.45,respectively.The correlation analysis of pharmacokinetic/pharmacodynamics showed that there was no significant correlation between the peak concentration of drug in plasma and the inhibitory effect of acid.Conclusion Compared with the 20 mg qd group and the 10 mg bid group,the acid inhibition effect is better,the administration times are less,and the safety of the two administration regimes is good.

Objective:To evaluate the predictive value of postnatal esophageal deviation index for clinical outcomes of fetuses with left-sided congenital diaphragmatic hernia (L-CDH).Methods:This retrospective study analyzed the clinical data of 103 neonates with prenatally diagnosed L-CDH who were admitted to Guangzhou Women and Children's Medical Center from January 2016 to February 2023. These patients were divided into the survival group ( n=82) and the death group ( n=21) according to the outcomes, and the extracorporeal membrane oxygenation (ECMO) group ( n=25) and the non-ECMO group ( n=78) according to whether ECMO support was required. Thoracoabdominal X-ray screening was performed on all neonates within 24 h after admission and the esophageal deviation index and cardiac deviation index were calculated. Independent sample t-test or Fisher's exact probability test were used to analyze the differences in general condition and postnatal imaging features between different groups. Receiver operating characteristic (ROC) curve was used to evaluate the value of postnatal imaging features in predicting the prognosis of L-CDH. Results:The esophageal deviation index and the cardiac deviation index of neonates in the survival group were lower than those in the death group [(10.5±5.3)% vs. (18.0±4.5)%, t=－5.47; (37.7±7.1)% vs. (42.8±8.2)%, t=－2.62; both P<0.05], while that were both higher in the ECMO group compared with the non-ECMO group [(18.0±4.3)% vs. (10.1±5.2)%, t=6.34; (42.4±7.9)% vs. (37.6±7.1)%, t=2.63; both P<0.05]. ROC curve showed that the area under the curve (AUC) for predicting the need for ECMO support was 0.879 (95% CI: 0.805-0.953) for esophageal deviation index and 0.712 (95% CI: 0.570-0.854) for cardiac deviation index, with the optimal cut-off values of 11.7% and 41.7%, respectively. The AUC for predicting the survival rate in patients with L-CDH by esophageal deviation index and cardiac deviation index were 0.854 (95% CI: 0.761-0.947) and 0.735 (95% CI: 0.582-0.887), respectively, with the corresponding optimal cut-off values of 15.8% and 41.7%. Conclusion:Postnatal esophageal deviation index is of value in predicting the need for ECMO support and survival rate in patients with L-CDH.

OBJECTIVE To explore the anti-inflammatory and antifungal action mechanism of taste-masked Lithospermum Saf-flower emulsion in vivo and in vitro.METHODS In vitro,the anti-inflammatory effect was detected by MTT assay,qPCR and ELISA.The anti-fungal effect of the product was investigated by broth dilution experiment,bactericidal kinetics,germ tube inhibition and XTT reduction test.In vivo,the effect was evaluated and the mechanism was investigated on the skin disease model of Candida al-bicans in mice.RESULTS Lithospermum in taste-masked Lithospermum Safflower emulsion had a significant inhibitory effect on the proliferation of RAW264.7 cells,and Safflower inhibited the production of IL-6 induced by LPS in a dose-dependent manner.Litho-spermum significantly inhibited the activity of Candida albicans,and its bactericidal mode is time-and concentration-dependent;Lithospermum significantly reduced the formation of Candida albicans germ tubes and destroyed its biofilm;Safflower had no direct kill-ing effect on Candida albicans,was not able to inhibit its biofilm formation,but significantly reduced the hyphal growth of Candida al-bicans and increased its ROS level.CONCLUSION The combination of Lithospermum and Safflower in the taste-masked Lithosper-mum Safflower emulsion can work synergistically to reduce inflammatory damage and treat Candida albicans infection of the skin.

Background and objective Small cell lung cancer(SCLC)is known as recalcitrant cancer with high malignancy and heterogeneity.Immunotherapy has changed the treatment pattern of extensive-disease SCLC(ED-SCLC),but the beneficiary population is limited.Therefore,exploring new therapeutic strategies is an urgent clinical problem to be solved for SCLC.SCLC is characterized by highly active glycolytic metabolism and pyruvate kinase Ml(PKM1)is one of the isozymes of PK,an important rate-limiting enzyme in glycolysis pathway.Previous studies have shown that PKM1 is related to autophagy and drug sensitivity,however,how PKM1 regulates drug sensitivity in SCLC and its mechanism remain unclear.The aim of this study was to investigate the biological functions of PKM1 in SCLC,including its effects on proliferation,migra-tion,autophagy,drug sensitivity,and expression of neuroendocrine(NE)-related markers in SCLC.Methods Western blot was used to detect the expression level of PKM1 in SCLC cells.PKM1 gene-overexpressed SCLC cell lines were constructed by stable lentivirus transfection.Proliferation of cells and drug sensitivity were detected by MTT,and migration ability of cells was determined by Transwell.The level of autophagy was detected by flow cytometry.Western blot was used to determine the expression levels of NE-related proteins.Results PKM1 was differentially expressed among various SCLC cell lines,and was lower in H1092 cells(P＜0.01).Compared with the control group,there was no significant difference in proliferation level of PKM1 overexpressing H1092 cell,but the migration ability was significantly increased(P＜0.001),the drug sensitivity was re-duced,and the level of autophagy was inhibited(P＜0.001).Additionally,overexpression of PKM1 could upregulate the expres-sion of non-neuroendocrine(non-NE)-related proteins(P＜0.01)and decrease the expression of NE-related proteins(P＜0.01).Conclusion PKM1 was differentially expressed in SCLC cell lines,and high expression of PKM1 did not affect the prolifera-tion,but affected the migration of SCLC cells.PKM1 might affect drug sensitivity by inhibiting autophagy and regulating the expression of NE markers.These results provide a theoretical basis for exploring the role of PKM1 in SCLC.

Pancreatic cancer is a high malignant tumor with insidious onset,early metastasis,and extremely poor prognosis.How to improve the early diagnosis and the prognosis of the patients is the current research focus.Although traditional surgical resection may improve the prognosis of some patients,the long-term effect is still poor.Biological benefit is the new mode of pancreatic cancer treatment,and it is crucial to do the whole process monitoring,precisely make the treatment plan and predict the effect under this mode.Artificial intelligence technology,with its powerful data processing and image recognition functions and high learning efficiency,can help to build relatively perfect prediction models with the cooperation of multidisciplinary experts,assist clinicians to make optimal plans,and make the pancreatic cancer patients benefit from precision medicine and individualized therapy.

Surface-enhanced Raman scattering(SERS)can detect molecules adsorbed on the surface of noble metals in monolayers and sub-monolayers,and provide structural information of molecules with high sensitivity,high accuracy,and fingerprint recognition and non-destructive detection.The SERS technology has been widely used in single-molecule detection,chemical reaction and engineering,biomedicine,nanomaterials and environmental detection,and so on.The spectral sensitivity and signal reproducibility of SERS are closely related to the type of noble metal substrate.In this paper,based on the mechanism of electromagnetic field enhancement(EM)and chemical enhancement(CM)of SERS,the affecting factors of SERS enhancement were analyzed,including the micro-nanostructure of SERS substrate,particle size,particle spacing,etc,the research and application of SERS substrate in recent years were summarized and reviewed,and the development direction of metal substrate,data analysis and application direction of SERS technology in the future were prospected.

Objective To investigate the incidence rate,clinical characteristics,and prognosis of neonatal stroke in Shenzhen,China.Methods Led by Shenzhen Children's Hospital,the Shenzhen Neonatal Data Collaboration Network organized 21 institutions to collect 36 cases of neonatal stroke from January 2020 to December 2022.The incidence,clinical characteristics,treatment,and prognosis of neonatal stroke in Shenzhen were analyzed.Results The incidence rate of neonatal stroke in 21 hospitals from 2020 to 2022 was 1/15 137,1/6 060,and 1/7 704,respectively.Ischemic stroke accounted for 75％(27/36);boys accounted for 64％(23/36).Among the 36 neonates,31(86％)had disease onset within 3 days after birth,and 19(53％)had convulsion as the initial presentation.Cerebral MRI showed that 22 neonates(61％)had left cerebral infarction and 13(36％)had basal ganglia infarction.Magnetic resonance angiography was performed for 12 neonates,among whom 9(75％)had involvement of the middle cerebral artery.Electroencephalography was performed for 29 neonates,with sharp waves in 21 neonates(72％)and seizures in 10 neonates(34％).Symptomatic/supportive treatment varied across different hospitals.Neonatal Behavioral Neurological Assessment was performed for 12 neonates(33％,12/36),with a mean score of(32±4)points.The prognosis of 27 neonates was followed up to around 12 months of age,with 44％(12/27)of the neonates having a good prognosis.Conclusions Ischemic stroke is the main type of neonatal stroke,often with convulsions as the initial presentation,involvement of the middle cerebral artery,sharp waves on electroencephalography,and a relatively low neurodevelopment score.Symptomatic/supportive treatment is the main treatment method,and some neonates tend to have a poor prognosis.

One patient was admitted to a hospital due to"sepsis,chronic kidney disease,type 2 diabetes,shock,and cerebral infarction".Patient's blood specimen was taken for clinical examination.Aerobic and anaerobic culture results of catheter blood and venous blood were both positive.The pathogen was identified as Staphylococcus pas-teuri by VITEK MS,and the patient was diagnosed as catheter-related bloodstream infection caused by Staphylo-coccus pasteuri.Clinical empirical use of piperacillin for anti-infection treatment was ineffective,and vancomycin was eventually used for treatment based on in vitro antimicrobial susceptibility testing.Patient's condition improved after removing the venous catheter.There are currently no reported cases of Staphylococcus pasteuri in China.Ear-ly identification of pathogen and adjustment of treatment plans based on antimicrobial susceptibility testing results are crucial for effective treatment of this case.

Objective To investigate the role and mechanism of miR-519d in brain metastasis(BM)of non-small cell lung cancer(NSCLC).Methods RT-PCR was used to detect the expression of miR-519d in normal lung tissues adjacent to cancer,NSCLC lung tissues,NSCLC brain tissues in NSCLC patients with or without BM,human NSCLC cell lines(SK-MES-1,NCI-H226,NCI-H1299,and NCL-H820),normal human bronchial epithelial cells(HBECs),human brain microvascular endothelial cells(HBMECs),and normal human astrocytes(NHA).NSCLC cell line NCI-H1299 was transfected with either miR-519d overexpression lentivirus(OE-miR-519d-LV)or empty vector lentivirus(NC-LV),and set as the OE-miR-519d-LV group and the NC-LV group;cells co-transfected with OE-miR-519d-LV and pcDNA3.1-HER3 were designated as the OE-miR-519d-LV+pcDNA3.1-HER3 group.The cells of the OE-miR-519d-LV group and the NC-LV group were injected intracardially into nude mice to establish an animal model of NSCLC with BM,and the mice were divided into the Ctrl group and the miR-519d group based on the injected cells.Bioluminescence imaging was used to observe NCI-H1299 cell metastasis in the brain of mice.The CCK-8 assay was used to determine the proliferation of NCI-H1299 cells in the OE-miR-519d-LV group and the NC-LV group.An in vitro blood-brain barrier(BBB)model was established using HBMECs and NHA-coated Transwell chambers,and the transendothelial migration ability of NCI-H1299 cells was detected.Western blot was used to detect the expression of epithelial-mesenchymal transition(EMT)-related proteins of MMP-2,MMP-9,E-cadherin,N-cadherin,and Vimentin in each group.Bioinformatics analysis was used to identify the potential binding sites between miR-519d and HER3,and their targeted regulatory relationship was validated by dual-luciferase gene reporter assays.Results Compared with the normal lung tissues adjacent to cancer,miR-519d expression was reduced in the NSCLC lung tissues and NSCLC brain tissues(P<0.05);miR-519d expression was lower in NSCLC brain tissues compared with the NSCLC lung tissues(P<0.05).Compared with HBECs,miR-519d expression was reduced in NSCLC cell lines(P<0.05),with lower levels in NCI-H1299,NCI-H226,and NCL-H820 cells compared with SK-MES-1 cells(P<0.05).Nude mice in the miR-519d group had a lower incidence of BM and longer survival compared with those in the Ctrl group,with statistically significant differences(P<0.05).Compared with the NC-LV group,NCI-H1299 cells in the OE-miR-519d-LV group showed decreases in the proliferation viability,transendo-thelial migration ability,and protein expression of MMP-2,MMP-9,N-cadherin,and Vimentin(P<0.05),and an increase in the protein expression of E-cadherin(P<0.05).miR-519d had a targeted regulatory effect on HER3 protein expression.Compared with the OE-miR-519d-LV group,the migration ability of cells in the OE-miR-519d-LV+pcDNA3.1-HRE3 group was increased(P<0.05),the protein expression of MMP-2,MMP-9,N-cadherin and Vimentin was increased(P<0.05),and the expression of E-cadherin was decreased(P<0.05).Conclusion miR-519d expression is reduced in NSCLC with BM,and its upregulation can inhibit the BM of NSCLC by targeting HER3.

To evaluate the effectiveness and safety of implantable D-shant atrial shunt device in patients with severe pulmonary arterial hypertension(PAH)and right heart failure.A 53-year-old female patient diagnosed with severe idiopathic PAH and right heart failure,her WHO FC grade was Ⅳ.The right heart catheter and implantation of D-shant atrial shunt device were performed under local anesthesia on November 30,2021.A 6 mm×4 cm peripheral artery balloon was selected to dilate the atrial septum and a D-shant atrial shunt device with a fixed 4 mm diameter orifice was implanted into the heart.The clinical symptoms and hemodynamics of the patient was improved after the intervention.Implantation of atrial shunt device as a palliative therapy to established a right to left shunt is another strategy for treating patients with severe PAH in late period,which has good effectiveness and safety.It could be the last replacement therapy to improve symptoms and prolonged lives to drug resistant and severe PAH patients.